Radioactive drug for recurrent ependymoma and high-grade glioma
Part of Cancer clinical trials.
This trial tests a radioactive drug (Rhenium-186) injected directly into the brain tumor to see the highest safe dose for children and young adults with ependymoma or high-grade glioma that has come back or is not responding to standard treatments. It may help shrink the tumor without needing surgery right away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 21 years old (or up to 25 in certain cases).
- You have a single tumor no larger than 3.5 cm and 22.4 mL, or multiple tumors that are close together.
- Your tumor is above the tentorium (supratentorial) and not in the spine or involving the brain’s membranes (leptomeninges).
- You have good liver and kidney function, and your blood counts are within safe ranges.
- You have not had certain prior treatments like Bevacizumab within the last year or standard radiation within 12 weeks.
- You are able to perform daily activities with a performance status of at least 60%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a virus called DNX-2401, which is injected directly into the tumor, for children and young adults with high-grade brain tumors that have come back or are hard to treat. The goal is to see if this virus can shrink or control the tumor.
This early-phase study tests a more precisely targeted type of radiation for children with ependymoma, aiming to treat the brain tumor more accurately. It may help reduce how much healthy tissue gets radiation, and researchers are checking safety and best dosing.
This early-phase study tests a drug made of tiny fat-like particles carrying rhenium for recurrent (coming back) high-grade glioma. It mainly checks safety and the highest tolerable dose, and it also looks for signs the treatment may slow tumor growth.
This Phase 1 trial tests whether a radioactive treatment delivered in tiny fat “packets” is safe and tolerable when given again to people whose glioma (brain tumor) came back after a previous similar treatment. It also looks at how well this re-treatment works in carefully selected patients.
This trial tests a radioactive nanoparticle drug given directly into the fluid around the brain and spine to treat cancer that has spread to the lining of the brain or spinal cord (leptomeningeal metastases). It aims to see if this targeted treatment is safe and might help shrink or control the cancer.
This early-stage trial tests a new radioactive drug called [177Lu]Lu-XT771 injected directly into the brain cavity after glioblastoma surgery. It measures whether the drug is safe and helps slow tumor regrowth in patients whose cancer has come back after earlier treatments.
Hear when a new Ependymoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.